Company intelligence / Profile preview
Pharos iBio
Anyang-si, South Koreapharosibio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Pharos iBio specializes in developing novel drugs for rare and refractory diseases using an AI-driven big data healthcare platform. Their lead asset has reached Phase 1 clinical trials—the first such trial in Korea using an AI-based drug development approach. The pipeline includes programs targeting FLT3, KRAS gene, FGFRs, and FAK across oncology indications such as acute myeloid leukemia and lung/ovarian cancers. The company leverages its Chemiverse System to identify new targets and compounds efficiently.
- Therapeutic areas
- HematologyOncology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on Pharos iBio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pharos iBio.